- Investing Ideas
- U.K. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.K. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
AstraZeneca
Market Cap: UK£179.3b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£115.60
7D
-3.6%
1Y
-1.5%
Diaceutics
Market Cap: UK£123.1m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
DXRX
UK£1.45
7D
-4.6%
1Y
5.5%
hVIVO
Market Cap: UK£45.3m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.066
7D
-3.6%
1Y
-35.6%